Scalp cooling
What is it and how does it work?
- Medical Review: Meghan O'Regan Coleman, DNP, RN, CRNP-BC, AOCNP, ACHPN
Scalp cooling, or cold cap therapy, is a treatment that may help reduce or prevent hair loss from chemotherapy.
Some chemotherapy drugs can damage hair follicles and cause hair to fall out. Chemotherapy-induced hair loss, known as alopecia, affects up to 65% of people receiving infusions.
Scalp cooling involves wearing a cap, which is kept cold. Scalp cooling works by lowering the temperature of the scalp before, during, and after chemotherapy infusions. Cooling the scalp:
- Reduces blood flow to hair follicles so less chemotherapy reaches them
- Slows cell activity in the hair follicles, making them less likely to be damaged
For many people, scalp cooling can help them keep some or most of their hair during chemotherapy. Others may still experience hair loss or choose to stop because of:
- The feeling of cold or pressure from the cap
- Headache or dizziness
- The time required before and after each infusion
Scalp cooling is considered to be safe for people undergoing treatment for breast cancer. Research shows that scalp cooling is not associated with breast cancer spread to the scalp, and that it does not appear to have an effect on breast cancer survival.
If your healthcare team has recommended chemotherapy and you haven’t yet started it, and keeping your hair is important to you, ask about scalp cooling. To get the most benefit, you’ll need to begin cooling at your first chemotherapy session.
Scalp cooling to help prevent hair loss with Vered Stearns, MD
LBBC CEO, Jean Sachs, MSS, MLSP, talks with Vered Stearns, MD, director of the Women’s Malignancies Disease Group at Johns Hopkins University about the pros and cons of scalp cooling, what to know about hair types and processing, and the costs of scalp cooling therapy.
On this page
- What is scalp cooling or cold cap therapy?
- How does scalp cooling work?
- Types of scalp cooling systems
- How effective is scalp cooling at preventing hair loss?
- Caring for your hair during scalp cooling therapy
- FDA oversight of scalp cooling therapy
- NCCN guidelines on scalp cooling therapy
- Side effects
- Paying for scalp cooling treatment
- FAQs
What is scalp cooling or cold cap therapy?
Scalp cooling, also called cold cap therapy, is a way to reduce or prevent hair loss during chemotherapy.
During chemotherapy, certain cancer treatments can damage the hair follicles, the tiny openings in the skin that grow hair. This can cause hair to fall out. Hair loss caused by chemotherapy usually starts 1 to 3 weeks after treatment begins.
Scalp cooling lowers the temperature of the scalp, helping protect the follicles from damage. Keep in mind that:
- It doesn’t work for everyone, but many people who try it keep more of their hair.
- Hair that is lost during treatment usually grows back after chemotherapy ends.
If chemotherapy has been recommended for you and keeping your hair is important, talk with your care team about scalp cooling before your first infusion. Ask them if the infusion center offers scalp cooling. It works best when started at the very beginning of treatment.
How does scalp cooling work?
Scalp cooling works by gently lowering the temperature of your scalp to slow the blood flow in that area. This helps protect your hair follicles from chemotherapy.
During scalp cooling, a snug cold cap is placed and worn before, during, and after the infusion session. Here’s how it helps:
- Blood vessels constrict. Cooling causes the small blood vessels in your scalp to narrow, so less chemotherapy medicine reaches your hair follicles.
- Cell activity slows. Cold temperatures slow how quickly cells divide in the follicles. Because chemotherapy targets fast-dividing cells, slowing them down helps reduce damage.
- Hair follicles stay stronger. By protecting the follicles, cooling can lower your chance of losing hair or reduce how much you shed.
Scalp cooling starts about 30 minutes before chemotherapy begins and continues through the infusion and for a short time afterward—often around 90 minutes, depending on the manufacturer’s directions.
Types of scalp cooling systems
There are two main ways scalp cooling is done during chemotherapy:
- Refrigerated scalp cooling systems, available in many cancer treatment infusion centers
- Cold caps, which are manually chilled and brought from home
Both work by keeping the scalp cold to help protect hair follicles from chemotherapy.
Refrigerated scalp cooling systems
Refrigerated scalp cooling systems use a small machine to keep the cooling cap cold throughout the infusion. The machine circulates chilled liquid through tubes inside the cap.
These systems are usually in cancer centers and infusion rooms, where staff can help fit and monitor the cap for treatment.
Examples include:
- Paxman scalp cooling system
- DigniCap scalp cooling system
- Amma portable scalp cooling system
Key differences between refrigerated systems:
- Paxman and DigniCap are infusion room-based systems.
- Amma is a portable system. You can leave the infusion chair and complete your scalp cooling anywhere in the infusion center.
These refrigerated systems are FDA-cleared and most often used in infusion centers because they maintain a steady, safe cooling temperature throughout treatment.
What to expect:
- A healthcare professional will fit the cap to your head before your first chemotherapy infusion.
- You’ll wear the cap:
- Before treatment begins, about 30-45 minutes
- During treatment (how long depends on your care team’s recommendations)
- After treatment is finished, usually for about 90 minutes, depending on the system you use
- During cooling sessions, the cap may feel cold or tight at first. This sensation usually improves within 10–15 minutes.
Cold caps
Cold caps are another way to cool the scalp. This type of scalp cooling does not use a machine. Instead, each cap is pre-frozen using dry ice or a special freezer.
Here’s how cold caps work:
- You bring several caps to your infusion session in a cooler or freezer cart.
- Each cap stays cold for about 30 minutes. As the cap becomes warm, it needs to be replaced with a new frozen one.
- You’ll likely need a friend or family member to help swap caps quickly and to help fit the new cap snugly.
This type of scalp cooling is sometimes called “manual” because the cold caps aren’t attached to a machine.
Cold cap options include:
- Arctic Cold Caps
- Penguin Cold Caps
- Chemo Cold Caps
- Wishcaps
Some cold cap companies offer training sessions, either in person or online, to teach you and your support person how to use them correctly.
Some treatment centers have special freezers for cold caps. Others do not. Cold cap manufacturers have information on how to find coolers, freezers, and dry ice.
Cold caps are not FDA-cleared yet, which means infusion centers can’t supply them directly. Still, many people rent them on their own and find they work well.
How effective is scalp cooling at preventing hair loss?
Research shows that scalp cooling can help many people keep some or most of their hair during chemotherapy, although results can vary widely.
How well scalp cooling works depends on several factors, including:
- The type of chemotherapy you receive
- The dose and schedule of chemotherapy
- Your hair type and texture
- Your age and overall hair health
Some people find that scalp cooling reduces their hair loss enough that they do not need to wear a wig or head covering. Others may still have a lot of hair thinning, even when cooling is used correctly.
If you’re considering scalp cooling, talk with your oncology team about:
- Whether your infusion center offers scalp cooling, and if so, what type
- If your type of recommended chemotherapy will affect how well the scalp cooling works
- What results other people have experienced with similar treatments
Even though results are different for each person, studies show that scalp cooling can work well for many people, and that most people who try it are satisfied with the results.
Chemotherapy type and dose
Scalp cooling success can depend on the type and amount of chemotherapy a person receives.
Studies have shown that scalp cooling can be very effective for some chemotherapy drug regimens and less effective for others.
2024 Dutch scalp cooling registry study
The largest study of scalp cooling looked at 7,424 people across 68 hospitals using Paxman and DigniCap systems in the Netherlands. The researchers found:
- 56% of participants did not wear a head covering, and
- 53% reported a small amount of hair loss by the end of their final treatment
- Effectiveness depended on chemotherapy type:
- Taxane regimens: 78% success rate; taxane chemotherapy includes the drugs docetaxel (Taxotere), paclitaxel (Taxol), and nab-paclitaxel (Abraxane).
- Anthracyclines: 40% success rate; anthracyclines include doxorubicin (Adriamycin) and epirubicin (Ellence)
- Combination anthracycline + taxane: 45% success rate
- People receiving lower doses of chemotherapy had better outcomes than those receiving higher doses of the same drugs.
- No other individual or lifestyle factors significantly affected results, and outcomes were similar across genders.
Researchers concluded that scalp cooling is effective for the majority of patients receiving chemotherapy for breast and other cancers.
Past Paxman and DigniCap clinical trials
Earlier clinical trials of these systems showed similar effectiveness by drug type:
- Paxman scalp cooling system trial (SCALP trial, U.S., 2017):
- 59% success in people receiving taxane-based chemotherapy
- 16% success in those receiving anthracyclines
- DigniCap scalp cooling system trial (U.S., 2016):
- 66% overall success rate (anthracyclines were not included)
- Higher doses of chemotherapy were linked to lower success rates
Across studies, “success” was typically defined as not needing a wig or keeping at least 50% of hair during treatment.
Amma study
A small 2024 study of the Amma portable refrigerated system in 14 people reported similar outcomes to Paxman and DigniCap systems. Because the study was done in a very small number of people, researchers said that more studies are needed to confirm its effectiveness in larger, more diverse groups.
Cold cap research
- In a small study of Penguin Cold Caps, 61% of people avoided hair loss from chemotherapy.
- Keeping hair depended on the type of chemotherapy given. People receiving anthracycline regimens were less likely to keep their hair.
Study takeaways
The key takeaways from these studies are:
- Scalp cooling tends to work best with taxane-based chemotherapy and lower-dose regimens.
- Results varied by person and treatment type. Most people using refrigerated systems reported some level of hair preservation.
- If keeping your hair is important to you, ask your care team whether your infusion center offers scalp cooling.
If you’re planning scalp cooling, ask if your care team can help you make any small adjustments—such as parting or dampening your hair before fitting the cap—to improve scalp contact and comfort.
Hair type
Researchers haven’t yet done large studies on how hair type affects scalp cooling results. Still, many oncologists and nurses have noticed some patterns in the clinic:
- Thinner or straighter hair often cools more evenly and may respond better to scalp cooling.
- Thicker, wavy, or curly hair can make it harder for the cap to stay in full contact with the scalp, which may reduce how well cooling works.
- Research suggests that scalp cooling may not work as well to preserve hair in Black women. Experts recommend wetting the hair or adding conditioner to the scalp before putting on the cap so the cap fits more tightly. Too much water can cause the hair of Black women to become curly and bulky. This can prevent the cap from fitting as well as it could. In a 2020 Journal of Clinical Oncology letter to the editor, doctors at Johns Hopkins School of Medicine shared observations and suggestions for Black women preparing for scalp cooling:
- Remove any hair extensions. This helps the cold temperature reach the scalp.
- For natural hair that has not been chemically straightened or relaxed, use heat to straighten the hair, and apply grease to the ends of the hair. When you wet your hair, focus only on the scalp area.
- If your hair is chemically straightened or relaxed, follow the scalp cooling manufacturer’s recommendations for hair preparation. It is okay to wet your hair before scalp cooling.
- Read the letter to learn more.
Age
A large study in the Netherlands (2012) found that scalp cooling worked better in younger people than in older people. Researchers believe this may be due to:
- Hair becomes more brittle with age, and
- Older hair may break more easily, even when follicles are protected.
That said, age alone doesn’t determine success. Many older adults still report positive results with scalp cooling—especially when the cap fits well and is used consistently throughout treatment.
Caring for your hair during scalp cooling therapy
Taking care of your hair gently throughout chemotherapy can help reduce breakage and protect new growth while you use scalp cooling.
Experts recommend focusing on gentle products, minimal styling, and patience before, during, and after treatment.
Tips for gentle hair care
- Avoid chemical treatments such as dyeing, bleaching, perming, or relaxing your hair.
- If you wear extensions or braids, remove them before you begin scalp cooling so the cap can fit closely to your scalp.
- Use mild, fragrance-free shampoos and conditioners that are sulfate-free.
- Wash your hair less often—for many people, once or twice a week is enough.
- Let your hair air dry instead of using heat tools like blow dryers or flat irons.
- Use a wide-tooth comb or soft brush and detangle gently, starting from the ends.
Hair care after chemotherapy is finished
Continue gentle care for about 2 months after your final infusion, as your scalp and hair follicles recover.
You may notice slower regrowth at first. This is normal. Hair often returns with a slightly different texture or color, which usually fades over time.
There’s no single proven hair care routine that improves scalp cooling success. Being gentle can help most people feel more comfortable and confident as their hair adjusts through treatment.
FDA oversight of scalp cooling therapy
The U.S. Food and Drug Administration (FDA) reviews and clears medical devices that are used to treat or manage side effects of cancer therapy, including hair loss prevention during chemotherapy.
Refrigerated scalp cooling systems are FDA-cleared for use in the U.S. They include:
- Paxman scalp cooling system
- DigniCap scalp cooling system
- Amma Portable Scalp Cooling System
These systems are considered medical devices because they connect to a machine that controls temperature during chemotherapy.
Cold caps, the kind you rent and freeze yourself, are not FDA-cleared yet. This means cancer centers can’t provide or store them on site, but it does not mean they’re unsafe or ineffective. Many people still use cold caps successfully by renting them directly from the manufacturer and following their care team’s guidance.
NCCN guidelines on scalp cooling therapy
The National Comprehensive Cancer Network (NCCN) develops evidence-based guidelines that help doctors manage cancer and its side effects.
In 2022, the NCCN added scalp cooling to its breast cancer treatment guidelines as a Category 2A recommendation.
That means:
- There is strong agreement among experts that scalp cooling works to help prevent chemotherapy-related hair loss.
- More research is still being done to strengthen the evidence.
If you’re planning to start chemotherapy, ask your cancer care team if scalp cooling is available, as described in the hair loss recommendations set by NCCN guidelines.
Side effects of scalp cooling therapy
Scalp cooling is generally safe, but it can cause temporary discomfort for some people. Most side effects are mild and go away soon after the cap is placed.
Common side effects
- Headache or pressure from the tight fit of the cap
- Feeling very cold on the scalp and upper body
- Neck or shoulder stiffness from the weight of the cap
- Dizziness or nausea, especially during the first few sessions
These sensations usually lessen after the first 10–15 minutes of cooling as your scalp adjusts to the temperature.
When to tell your care team about side effects
Let your nurse or oncologist know if you feel:
- Pain that doesn’t ease with repositioning or over-the-counter medicine
- Dizziness, nausea, or chills that last after treatment
- Frostbite-like pain (pins, needles) or blisters on your scalp (this is very rare)
Your team may adjust the fit or cooling time to make you more comfortable.
Studies show that most people do not stop scalp cooling because of side effects. Only about 3%–12% of people are reported to stop scalp cooling for comfort-related reasons.
Paying for scalp cooling treatment
Scalp cooling can help many people keep their hair during cancer treatment with chemotherapy. It may also involve added costs.
In this section, we’ll explain what to expect when paying for scalp cooling, including:
- Typical expenses
- New 2026 insurance billing codes
- Programs that may help make treatment more affordable
Paying for refrigerated scalp cooling
In 2022, the Centers for Medicare and Medicaid Services (CMS) approved insurance reimbursement for refrigerated scalp cooling. There are now two Current Procedural Terminology codes, or CPT codes, for refrigerated scalp cooling units used at chemotherapy infusion centers. Healthcare providers across the U.S. use these codes to bill insurance companies for medical services.
Reimbursement codes for refrigerated scalp cooling
In 2021, Centers for Medicare & Medicaid Services (CMS) issued two temporary Category III CPT codes for refrigerated scalp cooling: 0662T and 0663T. This includes reimbursement for use of the Paxman, DigniCap, and Amma scalp cooling systems.
- 0662T is used for initial cap measurement and fitting, as well as adjustment of cooling intensity tailored to your chemotherapy regimen.
- If your treatment plan includes multiple chemotherapy infusions, the single 0662T reimbursement covers measurement and fitting once.
- 0663T applies to cap placement, monitoring, and removal during each session.
- Each time you use the cap, your provider bills your insurance company with the 0663T code.
- Reimbursement amounts for the 0663T code can vary.
What’s changing in 2026
Starting January 1, 2026, the temporary Category III codes (0662T and 0663T) will be replaced by new, permanent Category I CPT codes for refrigerated scalp cooling in infusion centers. This includes the Paxman, DigniCap, and Amma scalp cooling systems.
The new Category I CPT codes are:
- Code 97007 for initial cap fitting and education: Medicare coverage will be $1,696.77 per person, per course of treatment (multiple chemotherapy sessions and rest periods)
- Code 97008 for each pre-infusion cooling session: Medicare coverage will be $10 per chemotherapy session
- Code 97009 for each 30 minutes of post-infusion cooling: Medicare coverage will be $6.35 for each 30 minutes per chemotherapy session
It’s important to know that these codes will not apply to non-refrigerated cold caps you bring to the infusion center in a cooler, such as Penguin, Arctic, Chemo, or Wishcaps cold caps.
Until 2026, 0662T and 0663T remain the active reimbursement codes for refrigerated scalp cooling. Future coverage under private insurers may vary. If you are using or planning to use refrigerated scalp cooling, talk with your insurance company and billing team about what the 2026 changes mean for your situation.
Learn more about paying for using the DigniCap System and the Paxman System.
Paying for cold caps
Cold cap costs vary depending on the company, your treatment schedule, and how much support you choose. On average, people can expect to pay:
- $300–$600 per chemotherapy session, or
- $380–$600 per month for cap rentals
Some advocacy groups and hospitals use $500 per infusion as a general estimate for cold cap cost planning. This can include:
- Cold cap rental fees
- Cold cap equipment security deposits (often refundable)
- Shipping costs
- Dry ice costs
- Optional help from a trained cold cap technician who assists with changing caps during treatment
Costs may be higher or lower depending on the provider and location.
Payment assistance
Because insurance coverage for cold caps is uncommon, many organizations and nonprofits help people afford cold caps:
- The Rapunzel Project, Hair to Stay, and Sharsheret offer help to people who have a financial need.
- Some hospitals and infusion centers also partner with local foundations or sponsor small grants for cold caps.
Before you rent
Before ordering a cold cap, talk with your care team about:
- Which brands they’ve seen work best with your type of chemotherapy
- How long you’ll need to rent caps
- Whether your infusion center can store caps in a freezer between sessions
- Whether your cancer center has information about financial assistance for cold caps
Some common brands of cold cap are:
Scalp cooling FAQs
Here are answers to some frequently asked scalp cooling questions.
How do I know if scalp cooling will work for me?
A great place to start is talking with your oncologist about what type of breast cancer treatment you’ll receive. Scalp cooling only works for some types of chemotherapy, not all.
Your hair type may also affect how well cold caps work. The company that provides the Paxman Cooling System has a decision making guide that can help.
Where can I buy a cold cap for chemo?
Cold caps can be rented from the companies that make them. Many of these companies offer plans that include:
- A cooler and hand truck for transporting caps
- Video or in-person training
- Resources to make using the caps easier
Consider the brands listed above or ask your cancer center which brand they recommend. The Rapunzel Project makes recommendations on cold caps and may also be a good resource.
If you search for cold caps online, chances are you’ll find low-cost products on Amazon or other sites that claim their caps work during chemotherapy. It’s important to choose a cap that has been vetted by your cancer care team and approved by your cancer treatment center.
Before you buy products from any company, talk to your care team about whether it will work for you.
What is the best cold cap or scalp cooling system available?
No one scalp cooling system can be called the “best.” However, some research has suggested that refrigerated scalp cooling systems such as Paxman and DigniCap are easier to use and may be more effective than manual cold caps in some people.
How well do cold caps actually work to prevent hair loss?
Scalp cooling therapy includes:
- Refrigerated systems offered at cancer centers, such as Paxman, DigniCap, and Amma
- Cold caps that you rent and bring with you to chemotherapy sessions, such as Penguin Cold Caps, Arctic Cold Caps, Chemo Cold Caps, and Wishcaps
Scalp cooling works by slowing blood flow to the hair follicles, which helps protect them from the effects of chemotherapy.
Effectiveness of refrigerated scalp cooling systems:
- The SCALP trial found that the Paxman scalp cooling system was successful in 59% of people receiving taxane-based chemotherapy and 16% of those receiving anthracycline chemotherapy.
- A similar trial using the DigniCap system found scalp cooling successful in 66% of participants, though no one in this study received anthracycline chemotherapy.
- Higher chemotherapy doses were linked to lower success rates.
- Even when scalp cooling was successful, most people experienced some hair loss—but usually not enough to require a wig. Success was defined as either keeping at least 50% of hair or not needing a wig during treatment.
Effectiveness of cold caps:
- A small study of Penguin Cold Caps found that 61% of participants avoided chemotherapy-induced hair loss.
- Success can depend on chemotherapy type: people receiving anthracycline regimens were less likely to maintain their hair.
Are cold caps painful?
A possible side effect of cold caps is scalp pain that is caused by the extreme cold. The discomfort usually improves after the first few minutes of cooling as your scalp adjusts to the temperature.
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
Reviewed and updated: December 9, 2025
Reviewed by: Meghan O'Regan Coleman, DNP, RN, CRNP-BC, AOCNP, ACHPN
Tagged:
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy
- second-look surgery
- second primary cancer
- secondary cancer
- secrete
- sedative
- segmental mastectomy
- selection bias
- selective estrogen receptor modulator
- selective serotonin reuptake inhibitor
- sentinel lymph node
- sentinel lymph node biopsy
- sentinel lymph node mapping
- sepsis
- sequential AC/Taxol-Trastuzumab regimen
- sequential treatment
- SERM
- sertraline
- Serzone
- sestamibi breast imaging
- sexuality
- sibling
- side effect
- silicone
- simple mastectomy
- simulation
- Single-agent therapy
- sleep disorder
- social service
- social support
- social worker
- sodium thiosulfate
- soft tissue
- solid tumor
- somatic
- somatic mutation
- sorafenib
- specialist
- specificity
- spiculated mass
- spinal anesthesia
- spinal block
- spiral CT scan
- spirituality
- sporadic cancer
- SSRI
- stable disease
- stage
- stage 0 breast carcinoma in situ
- stage 0 disease
- stage I breast cancer
- stage IA breast cancer
- stage IB breast cancer
- stage II breast cancer
- stage II breast cancer
- stage IIA breast cancer
- stage IIB breast cancer
- stage III breast cancer
- stage III lymphedema
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- staging
- stamina
- standard of care
- standard therapy
- statistically significant
- stent
- stereotactic biopsy
- stereotactic radiosurgery
- sterile
- sternum
- steroid
- stress
- strontium
- study agent
- subcutaneous
- subcutaneous port
- subjective improvement
- subset analysis
- supplemental nutrition
- supplementation
- support group
- supportive care
- supraclavicular lymph node
- surgeon
- surgery
- surgical biopsy
- surgical menopause
- surgical oncologist
- survival rate
- symptom
- symptom management
- symptomatic
- synergistic
- synthetic
- syringe
- systemic
- systemic chemotherapy
- systemic disease
- systemic therapy
- TAC regimen
- tai chi
- tailored intervention
- talk therapy
- tamoxifen
- targeted therapy
- taxane
- Taxol
- Taxotere
- Tc 99m sulfur colloid
- technician
- terminal disease
- therapeutic
- therapeutic touch
- therapy
- thermography
- thiethylperazine
- thiotepa
- third-line therapy
- thrush
- time to progression
- tinnitus
- tissue
- tissue flap reconstruction
- TNM staging system
- tomography
- tomotherapy
- topical
- topical chemotherapy
- topoisomerase inhibitor
- total estrogen blockade
- total mastectomy
- total nodal irradiation
- total parenteral nutrition
- toxic
- toxicity
- tracer
- traditional acupuncture
- tranquilizer
- transdermal
- transfusion
- transitional care
- translational research
- trastuzumab
- trauma
- treatment field
- trigger
- trigger point acupuncture
- triple-negative breast cancer
- tumescent mastectomy
- tumor
- tumor antigen vaccine
- tumor board review
- tumor burden
- tumor debulking
- tumor load
- tumor marker
- tumor volume
- Tykerb
- ulcer
- ulceration
- ultrasound-guided biopsy
- ultrasound/ultrasonography
- ultraviolet radiation therapy
- uncontrolled study
- undifferentiated
- unilateral
- unilateral salpingo-oophorectomy
- unresectable
- unresected
- upstaging
- urticaria
- VACB
- vaccine therapy
- vacuum-assisted biopsy or vacuum-assisted core biopsy
- Valium
- vancomycin
- vandetanib
- vascular endothelial growth factor-antisense oligonucleotide
- vascular endothelial growth factor receptor tyrosine kinase inhibitor
- vein
- Velban
- venipuncture
- venous sampling
- Versed
- vertebroplasty
- vinorelbine
- vital
- vomit
- watchful waiting
- wedge resection
- Wellcovorin
- Western medicine
- WGA study
- white blood cell
- whole cell vaccine
- whole genome association study
- wide local excision
- wire localization
- wound
- X-ray therapy
- Xanax
- Xeloda
- xerostomia
- Xgeva
- yoga
- ziconotide
- Zinecard
- Zofran
- zoledronic acid
- Zoloft
- Zometa
Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.